SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE

                         SECURITIES EXCHANGE ACT OF 1934



Date of report (Date of earliest event reported)  October 25, 2001
                                                  ----------------

                         BIO-IMAGING TECHNOLOGIES, INC.
              ----------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)


    Delaware                           1-11182                  11-287-2047
--------------------------------------------------------------------------------
(State or Other Jurisdiction   (Commission File Number)      (IRS Employer
    of Incorporation)                                        Identification No.)



826 Newtown-Yardley Rd., Newtown, PA                                 18940
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)                           (Zip Code)


                                 (267) 757-1360
                          -----------------------------
                         (Registrant's telephone number,
                              including area code)



           -----------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)




     ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.

     On October 25, 2001 (the "Closing Date"), Bio-Imaging Technologies, Inc., a
Delaware   corporation  (the   "Company"),   consummated  the  acquisition  (the
"Acquisition")  of  assets of the  Intelligent  Imaging  business  ("Intelligent
Imaging") of Quintiles,  Inc., a North  Carolina  corporation  and  wholly-owned
subsidiary of Quintiles Transnational Corp.  ("Quintiles").  Intelligent Imaging
specializes in providing  digital medical  imaging  services for clinical trials
and the  health  care  industry,  a line of  business  the  Company  intends  to
continue.  In the  Acquisition,  the Company acquired  substantially  all of the
assets of  Intelligent  Imaging and assumed  certain  liabilities of Intelligent
Imaging  pursuant to the terms and conditions of the Asset  Purchase  Agreement,
dated as of October 25,  2001,  by and between  the Company and  Quintiles  (the
"Asset Purchase Agreement"). The description and defined terms, unless otherwise
indicated,  contained in this Item 2 of the transactions consummated pursuant to
the Asset  Purchase  Agreement  is qualified in its entirety by reference to the
full text of the Asset Purchase  Agreement,  a copy of which is attached to this
Report as Exhibit 2.1 and is incorporated by reference herein.

     The assets acquired  included  Intelligent  Imaging's  customer  contracts,
equipment,  permits,  leases and proprietary  rights.  In consideration  for the
assets purchased, the Company made payment to Quintiles of an aggregate purchase
price  consisting  of  $1,000,000  in the  form  of an  unsecured,  subordinated
convertible  promissory  note, dated as of October 25, 2001, made by the Company
payable to Quintiles  (the "Note") in the  principal  amount equal to $1,000,000
with  interest  per  annum  equal  to the rate in  effect  on the  business  day
immediately  prior to the date on which payments are due under the Note equal to
the Three-Month London Interbank Offering Rate as published from time to time in
the Wall Street  Journal plus 300 basis points,  compounded  annually based on a
365-day year. The Note, which is payable in quarterly  installments with respect
to fifty  percent  (50%) of the  aggregate  principal  amount  together with all
outstanding  interest,  matures thirty-six (36) months from the Closing Date and
is  convertible by Quintiles any time prior to maturity into a maximum number of
1,103,753 shares of the Company's  common stock,  $.00025 par value (the "Common
Stock").  The  number  of  shares of  Common  Stock  into  which the Note may be
converted could be less than 1,103,753,  depending on the market price per share
of the Common Stock on the date of  conversion,  and the  outstanding  principal
balance as of any such  conversion.  A copy of the Note is filed as Exhibit  4.1
hereto and is incorporated by reference  herein.  The Company may pay Additional
Consideration  in  accordance  with the  provisions  as set  forth in the  Asset
Purchase  Agreement  (the  maximum  number of  shares to be issued to  Quintiles
pursuant to such provision is 646,247 shares of Common Stock which is to be paid
out, in no event,  later than  February  15,  2003).  The Company  also  assumed
certain  liabilities  of  Intelligent  Imaging,  including  all  obligations  of
Intelligent  Imaging  arising  after the Closing  under  certain  contracts  and
unearned  income  reflected  on the closing  balance  sheet,  except for certain
retained liabilities.

     The principles  followed in determining the amount of consideration paid in
the Acquisition were based upon negotiations  between  unaffiliated parties and,
among other factors:  (i) the financial and operating  performance and prospects
of the Company after giving effect to the Acquisition; (ii) the proposed tax and
accounting  treatment  to be  accorded  the  Acquisition;  (iii)  the  value and
composition of Intelligent  Imaging's assets; and (iv) the financial  statements
and other relevant financial and operating data of Intelligent Imaging. Prior to
the Acquisition,

                                     - 2 -


there were no material  relationships  between Quintiles or its shareholders and
the Company or any of the Company's  affiliates,  any director or officer of the
Company, or any associate of such director or officer.

     A copy of the press release  announcing the execution of the Asset Purchase
Agreement is attached  hereto as Exhibit 99.1 and is  incorporated  by reference
herein.

     ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

     (a) Financial Statements of Business Acquired.

     To be filed by amendment.  The Company believes that it is impracticable to
provide such financial information as of the date hereof. Such information shall
be filed with the  Securities  and Exchange  Commission no later than January 8,
2001.

     (b) Pro Forma Financial Information.

     To be filed by amendment.  The Company believes that it is impracticable to
provide such financial information as of the date hereof. Such information shall
be filed with the  Securities  and Exchange  Commission no later than January 8,
2001.

     (c) Exhibits.

         2.1   Asset  Purchase  Agreement,  dated as of October 25, 2001, by and
               between the Company and Quintiles.*

         4.1   Promissory  Note,  dated  as of  October  25,  2001,  made by the
               Company payable to Quintiles.

         99.1  Press Release, dated October 29, 2001, regarding the consummation
               of the Acquisition.

     *The  schedules or exhibits to this  document are not being filed  herewith
because the  Company  believes  that the  information  contained  therein is not
material.  Upon request therefor, the Company agrees to furnish supplementally a
copy of any schedule or exhibit to the Securities and Exchange  Commission  (the
"SEC").

     ITEM 8. CHANGE IN FISCAL YEAR

     On November 6, 2001, the Company's board of directors  approved a change in
the  Company's  fiscal year end from  September 30 to December 31. The report on
Form 10-QSB  covering the three months ended  December 31, 2001 (the  transition
period) will be filed in accordance with the SEC filing requirements.

                                     - 3 -





                                    SIGNATURE
                                    ---------

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                               BIO-IMAGING TECHNOLOGIES, INC.


                               By:  /s/ Mark L. Weinstein
                                    --------------------------------------------
                                    Name:  Mark L. Weinstein
                                    Title: President and Chief Executive Officer



November 9, 2001